One email when the decision is public, with what it means in plain language. You'll also get new trials and FDA news for Narcolepsy Type 1. Unsubscribe anytime.
- Trial Alerts, when a new trial opens or a trial changes
- Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
The FDA is expected to decide on AXS-12 for Narcolepsy (cataplexy) by May 1, 2027, under an NDA from Axsome Therapeutics.
What the FDA is deciding on AXS-12 for Narcolepsy
The FDA is reviewing Axsome Therapeutics' application to approve AXS-12 (reboxetine) for narcolepsy (cataplexy). Norepinephrine reuptake inhibitor targeting cataplexy in narcolepsy.
Who the AXS-12 decision matters to
Narcolepsy type 1 is a chronic neurologic disorder caused by loss of hypocretin-producing neurons, resulting in severe daytime somnolence and cataplexy. HLA-DQB1*0602 association and brain imaging support the autoimmune hypothesis.
Medications enhance wakefulness; behavioral approaches optimize quality of life.
Prevalence: 1 in 2,000 to 3,000 people; often undiagnosed. See our full Narcolepsy Type 1 page for current treatments, recruiting trials, and community resources.
What an approval or a rejection of AXS-12 would mean
An approval starts a second race rather than ending the first one: specialty pharmacy setup, insurance review, and patient assistance typically take weeks even when everything goes right. Our guide to the 90 days after a rare disease approval explains the timeline and the moves families can make on day 1.
A complete response letter would mean the FDA declined to approve in the application's current form. The letter describes what the FDA wants addressed, and the company then decides whether to resubmit, run more studies or stop. Either way, this page updates with the outcome and what it means.
Where Narcolepsy Type 1 treatment stands today
Read our full Narcolepsy Type 1 treatment summary
Medications enhancing central nervous system wakefulness form the foundation of therapy: stimulants including modafinil (first-line), armodafinil, methylphenidate, and amphetamine derivatives manage excessive daytime sleepiness. Sodium oxybate (GHB) addresses both EDS and cataplexy and improves nighttime sleep, and it requires careful dosing and patient education.
Pitolisant, a histamine H3-receptor antagonist, offers an alternative mechanism for both EDS and cataplexy and is gaining clinical adoption. Selective serotonin or norepinephrine reuptake inhibitors (SSRIs/SNRIs) manage cataplexy alone.
In August 2026 the FDA approved oveporexton (Orzeyful), a twice-daily orexin receptor 2 agonist and the first medicine to directly target the loss of orexin signaling behind narcolepsy type 1, for adults.
It can be sold only after the DEA completes controlled substance scheduling, which Takeda expected by November 2026. Behavioral strategies including scheduled naps (10-20 minutes), strict sleep hygiene, avoidance of sedating medications, and comprehensive safety measures optimize quality of life.
Other orexin receptor 2 agonists, including ALKS 2680 (NCT07455383) and ORX750 (NCT06752668), are being tested in clinical trials.
Genetic counseling helps families understand disease mechanism and inheritance patterns. Work with sleep medicine specialists experienced in narcolepsy management.
The Narcolepsy Type 1 page has every treatment and trial →Meanwhile, 20 Narcolepsy Type 1 studies are open or about to open
Whatever the FDA decides here, research on Narcolepsy Type 1 does not stop. Of these, 18 test a treatment; the others follow patients over time. The most recently updated:
We'll email you when the decision is public, with what it means in plain language, and when new trials open for Narcolepsy Type 1. Unsubscribe anytime.
- Trial Alerts, when a new trial opens or a trial changes
- Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Frequently asked questions
When will the FDA decide on AXS-12?
The FDA's target date (PDUFA date) for AXS-12 in Narcolepsy (cataplexy) is May 1, 2027.
Who disclosed it: Axsome Therapeutics. The FDA does not publish these dates.
Can it move: the FDA can act early, and a major amendment to the application can push the date back 3 months.
Source: Axsome press release
What is AXS-12 being reviewed for?
Axsome Therapeutics submitted an NDA for AXS-12 in Narcolepsy (cataplexy).
What to know: Norepinephrine reuptake inhibitor targeting cataplexy in narcolepsy.
Is there already an FDA-approved treatment for Narcolepsy Type 1?
Yes. Trial Friend's drug list includes 1 FDA-approved drug for Narcolepsy Type 1.
Approved: Orzeyful (oveporexton).
Check: the Narcolepsy Type 1 page also searches FDA drug labels for approved treatments.
Can I get AXS-12 before the FDA decides?
Usually only through a clinical trial or an expanded access program, and the company decides whether to offer one.
Trials: 20 Narcolepsy Type 1 studies are open or about to open, 18 of them testing a treatment. See them.
Check your fit: Match Me compares your details with every open trial.
Expanded access: your doctor can ask Axsome Therapeutics directly. Registered programs are listed on ClinicalTrials.gov.
How much will AXS-12 cost?
Axsome Therapeutics has not announced a price. Drugmakers usually set it around approval.
Help paying: drugmaker programs and charity funds usually open at launch.
Find help: the patient assistance finder lists programs by insurance type.
What happens after the AXS-12 decision?
This page updates with the outcome the day it is announced.
If approved: getting the drug still takes time. Specialty pharmacy setup, insurance review and patient assistance often take weeks. Our guide covers what families can do on day 1.
If not approved: a complete response letter means the FDA declined the application in its current form. Many are about manufacturing or how data were presented, and companies often resubmit.
Where this date comes from
The FDA does not publish PDUFA dates; companies disclose them. This one comes from Axsome press release. Dates can move, and the FDA can act early or late. This page rechecks against our calendar, which is re-verified daily.